C-Reactive Protein: Higher During Acute Psychotic Episodes and Related to Cortical Thickness in Schizophrenia and Healthy Controls

about

C-Reactive Protein: Higher During Acute Psychotic Episodes and Related to Cortical Thickness in Schizophrenia and Healthy Controls

Item

http://www.wikidata.org/entity/Q58575852

description

wetenschappelijk artikel

@nl

наукова стаття, опублікована у 2018

@uk

name

C-Reactive Protein: Higher Dur ...... zophrenia and Healthy Controls

@en

C-Reactive Protein: Higher Dur ...... zophrenia and Healthy Controls

@nl

type

Item

label

C-Reactive Protein: Higher Dur ...... zophrenia and Healthy Controls

@en

C-Reactive Protein: Higher Dur ...... zophrenia and Healthy Controls

@nl

prefLabel

C-Reactive Protein: Higher Dur ...... zophrenia and Healthy Controls

@en

C-Reactive Protein: Higher Dur ...... zophrenia and Healthy Controls

@nl

P1476

C-Reactive Protein: Higher Dur ...... zophrenia and Healthy Controls

@en

P2093

Cherrie Galletly

http://www.w3.org/2001/XMLSchema#string

Clive Stanton

http://www.w3.org/2001/XMLSchema#string

Cynthia S Weickert

http://www.w3.org/2001/XMLSchema#string

Dennis Liu

http://www.w3.org/2001/XMLSchema#string

Hugh Powell

http://www.w3.org/2001/XMLSchema#string

Isabella Jacomb

http://www.w3.org/2001/XMLSchema#string

Jason Bruggemann

http://www.w3.org/2001/XMLSchema#string

Maryanne O'Donnell

http://www.w3.org/2001/XMLSchema#string

Rhoshel Lenroot

http://www.w3.org/2001/XMLSchema#string

Rohini Vasudevan

http://www.w3.org/2001/XMLSchema#string

P2860

C-reactive protein: a critical update

A double-blind, randomized study of minocycline for the treatment of negative and cognitive symptoms in early-phase schizophrenia

Minocycline benefits negative symptoms in early schizophrenia: a randomised double-blind placebo-controlled clinical trial in patients on standard treatment

Changes in serum interleukin-2, -6, and -8 levels before and during treatment with risperidone and haloperidol: relationship to outcome in schizophrenia

Adjuvant aspirin therapy reduces symptoms of schizophrenia spectrum disorders: results from a randomized, double-blind, placebo-controlled trial

The positive and negative syndrome scale (PANSS) for schizophrenia

Meta-analysis of cytokine alterations in schizophrenia: clinical status and antipsychotic effects

Prenatal infection and schizophrenia: a review of epidemiologic and translational studies.

Cerebral cortical hyperactivation in response to mental stress in patients with coronary artery disease.

The short-form version of the Depression Anxiety Stress Scales (DASS-21): construct validity and normative data in a large non-clinical sample.

P304

2230

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.3389/FIMMU.2018.02230

http://www.w3.org/2001/XMLSchema#string

P407

English

P478

http://www.w3.org/2001/XMLSchema#string

P50

Ryan Balzan

Thomas W Weickert

P577

2018-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

30364161

http://www.w3.org/2001/XMLSchema#string

P921

psychosis

schizophrenia

P932

6192380

http://www.w3.org/2001/XMLSchema#string